FDA Approves Verquvo for Chronic Heart Failure
The FDA has approved Verquvo (vericiguat), a drug jointly developed by Bayer and Merck, for treatment of symptomatic chronic heart failure.
The agency said it specifically approved the drug for “reducing the risk of cardiovascular death and heart-failure hospitalization following a hospitalization for heart failure or the need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45 percent.”
Merck holds the U.S. rights to Verquvo while Bayer has exclusive rights in the rest of the world. The companies are currently seeking approval for the drug in the European Union, Japan and China.